ÄMNESOMRÅDE
Psyllium – fröskal, fröpulver och vad fibermängden gäller
Psyllium används i fiberprodukter. Växtart, frö eller fröskal och mängd per portion behöver följa med när du jämför innehåll och forskning. [EMA-HUSK] [EMA-SEED] [P017] [P057] [P077] [P097]
Separat granskad . Källornas egna datum framgår av underlagen.
Frö och fröskal är olika växtmaterial
EMA skiljer ispaghula husk, fröskalen från Plantago ovata, från psyllium seed, hela eller pulveriserade frön från Plantago afra eller Plantago indica. De är besläktade fibermaterial men ska behålla sin art och växtdel. Ett gemensamt vardagsnamn räcker inte för att göra dem till samma råvara. [EMA-HUSK] [EMA-SEED]
Originalets namn får inte fyllas ut i efterhand
Fiberkomplex anger psylliumhuskpulver med namnet Plantago psyllium. Mason Natural anger uttryckligen Plantago ovata och husk. Pure Planet skriver Organic Psyllium Husk utan artnamn, medan Blessed skriver psyllium seed powder. Här behålls skillnaderna; ett saknat artnamn ersätts inte med EMA:s exempel. [P017] [P057] [P077] [P097]
1 000 mg fröskal är inte hela dospåsens vikt
Fiberkomplex deklarerar 1 000 mg psylliumhuskpulver per påse på 6 g. Samma påse innehåller bland annat 2 250 mg inulin och kiwifruktpulver. Påsens hela vikt är inte en mängd psyllium, och inulinraden ska hållas separat. [P017]
Pure Planet deklarerar 1 501 mg Organic Psyllium Husk per en matsked på 8,7 g. Tabellen namnger och mängdsätter även exempelvis linfrö, chiafrö och äppelfiber. Dessa rader beskriver andra ingredienser och ska inte läggas ovanpå psylliumraden. [P077]
2 000 mg gäller blandningen, inte enbart psyllium
Mason Natural anger 2 000 mg för en Proprietary Blend per fyra kapslar. Psyllium är en av flera namngivna delar. Det sparade originalet ger ingen separat psylliummängd. Blandningens total får därför inte föras över till den enskilda ingrediensen. [P057]
Blesseds tabell anger 1 g kostfiber per en skopa på 34 g, medan psyllium seed powder finns i den övriga ingredienslistan. Tabellen fördelar inte den sammanlagda kostfibern på enskilda ingredienser. Inte heller pulverportionens 34 g är en mängd psyllium. [P097]
Fibern binder vatten och används vid förstoppning
EMA beskriver hur fibermaterialet tillsammans med vatten bildar en gelliknande massa och gör avföringen mjukare. Bedömningen gäller växtbaserade läkemedel för bland annat vanlig förstoppning och situationer där mjukare avföring behövs. Den ger inget automatiskt läkemedelsgodkännande åt produkterna här. [EMA-HUSK] [EMA-SEED]
Väl etablerad användning är en bedömning med avgränsat underlag
För fröskalen redovisar EMA kliniska studier med över 900 patienter och beskriver små sänkningar av blodets kolesterolvärden i flera studier. Det senare är ett blodmått, inte ett redovisat bevis här för färre hjärtinfarkter. Användning vid högt kolesterol ska enligt EMA ske under medicinsk övervakning. [EMA-HUSK]
EMA:s uttryck well-established use innebär att det finns vetenskapliga litteraturdata om effekt och säkerhet vid den angivna användningen under minst tio år inom EU. För psylliumfrön beskriver sammanfattningen också att vissa slutsatser bygger på studier av liknande frön och fröskal. Det är inte samma sak som en separat studie av varje material eller produkt. [EMA-HUSK] [EMA-SEED]
Lindrad förstoppning är inte en generell behandling av tarmsjukdom
I sin sammanfattning om fröskal skiljer EMA mellan lindring hos personer som också hade förstoppning och effekt på själva tarmsjukdomen. Den skillnaden behöver följa med när forskningen återges. Produktnamn som Cleanser eller Parasite Cleanse visar inte i sig en effekt mot parasiter eller en särskild rening av kroppen. [EMA-HUSK] [P057] [P077]
Vätska, sväljning och andra läkemedel spelar roll
EMA framhåller att materialet ska tas med tillräckligt med vätska och skiljas i tid från andra läkemedel. Gasbildning, uppblåsthet och allergiska reaktioner kan förekomma. Att svälja materialet utan tillräcklig vätska kan ge problem med hård, torr avföring. Följ den aktuella produktens anvisningar och fråga apotek eller vård om samtidig medicinering. [EMA-HUSK] [EMA-SEED]
EMA avråder bland annat vid sväljsvårigheter eller förträngningar i mag-tarmkanalen, oförklarad ändtarmsblödning eller en plötslig förändring av avföringsvanor som kvarstår längre än två veckor. Besvären ska inte döljas med ett fiberpulver. Vid förstoppning som inte går över inom tre dagar anger EMA att läkare eller apotek bör kontaktas. [EMA-HUSK] [EMA-SEED]
Hela sammanfattningar visas med sin lästa omfattning
Här används hela de två offentliga EMA-översikterna om fröskal respektive frön, med sammanfattningar publicerade 2014. De fullständiga utredningsrapporterna och enskilda försöksoriginalen har inte granskats separat för denna sida. Det är en återgivning av dessa daterade myndighetssammanfattningar, inte en ny systematisk översikt. [EMA-HUSK] [EMA-SEED]
Följ rätt växtdel, portionsrad och underlag
Produktlänkarna visar hela sparade ingredienslistor och tabeller, inklusive övriga ingredienser och allergenuppgifter. Källpanelerna håller EMA:s bedömningar av fröskal och frön åtskilda. De deklarerade mängderna är innehållsexempel, inte personliga dosråd. [P017] [P057] [P077] [P097] [EMA-HUSK] [EMA-SEED]
Att ta med
- Behåll artnamn och växtdel: fröpulver, fröskal och ett ospecificerat psylliumnamn är inte utbytbara uppgifter. [EMA-HUSK] [EMA-SEED] [P017] [P057] [P077] [P097]
- Skilj den enskilda ingrediensens mängd från blandningens total, portionsvikt och total kostfiber. [P017] [P057] [P077] [P097]
Läs verkliga produktdeklarationer
Källor och hela underlag
EMA-HUSK · European Medicines Agency · HMPC
Complete official Overview on ispaghula husk, including all clinical, identity, risk and approval paragraphs plus displayed summary metadata; not the full assessment report or linked trials
URL: https://www.ema.europa.eu/en/medicines/herbal/plantaginis-ovatae-seminis-tegumentum Publisher: European Medicines Agency · HMPC Source date: 2013; public summary published2014-06-16 Captured: 2026-10-18T17:00:44.325575+00:00 Scope: Complete official Overview on ispaghula husk, including all clinical, identity, risk and approval paragraphs plus displayed summary metadata; not the full assessment report or linked trials Actual HTTP status: 200 Overview This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of ispaghula husk. The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing ispaghula husk. This summary is not intended to provide practical advice on how to use medicines containing ispaghula husk. For practical information about using ispaghula husk medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. Expand section Collapse section What is Ispaghula husk? Ispaghula husk is the common name for the seed coats of the plant Plantago ovata Forssk. The plant is cultivated or gathered to obtain the seeds for medicinal use. Ispaghula husk is used without further processing or as preparations obtained by powdering the seed coats. Herbal medicines containing ispaghula husk are usually available in solid forms to be taken by mouth. What are the HMPC conclusions on its medicinal uses? The HMPC concluded that ispaghula husk can be used for the treatment of habitual constipation (constipation not caused by a physical change to an organ) and in conditions where softening of the stools is desirable to reduce pain when they are passed, such as anal fissures, haemorrhoids and after surgery to the anus or rectum. The HMPC also concluded that ispaghula husk can be used in people where an increase in the daily intake of dietary fibre may be advisable, such as patients with irritable bowel syndrome who are suffering from constipation or in combination with diet in patients with hypercholesterolaemia (high blood cholesterol levels). Ispaghula husk should be taken with plenty of liquid. It should be taken during the day at least half an hour to one hour before or after taking other medicines and not immediately before bedtime. It can be used in adults and children above the age of 6 years for the treatment of constipation and to soften the stools but should only be used in adults and children over the age of 12 years when used to increase the fibre intake. If constipation does not resolve after three days, a doctor or pharmacist should be consulted. The use of ispaghula husk in hypercholesterolaemia always requires medical supervision. Detailed instruction on how to take ispaghula husk medicines and who can use them can be found in the package leaflet that comes with the medicine. How does ispaghula husk work as a medicine? Ispaghula husk contains dietary fibre, which when mixed with water forms a gel-like mass that works as a mild laxative (medicine used to treat constipation). It moves down the digestive system and makes the stools softer by increasing their water content. At the same time ispaghula husk lubricates the intestine which improves the transit of stools. By increasing the stool bulk it also increases the tension in the bowel wall which will trigger bowel movements. The way ispaghula husk works in reducing blood cholesterol levels is not fully understood. What evidence supports the use of ispaghula husk medicines? The HMPC conclusions on the use of ispaghula husk medicines are based on their 'well-established use' in these conditions. This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. In its assessment of ispaghula husk to treat constipation, the HMPC considered a number of clinical studies involving over 900 patients that showed the effectiveness of ispaghula husk as a mild laxative. Studies that were carried out in patients with irritable bowel disease did not show an effect on the disease itself but showed benefits in those patients who were also suffering from constipation. Its effectiveness in softening stools has been shown in a number of studies comparing ispaghula husk with placebo (a dummy treatment) in patients with haemorrhoids. Several studies investigated the effects of ispaghula husk on blood cholesterol levels and found that treatment with ispaghula husk led to small reductions in blood cholesterol levels. For detailed information on the studies assessed by the HMPC, see the HMPC assessment report. What are the risks associated with Ispaghula husk medicines? Side effects have been reported with ispaghula husk medicines, including flatulence and abdominal distension (swelling of the belly). There is a risk of a build-up of hard, dry stool, particularly if Ispaghula husk is swallowed without enough liquid. Allergic reactions including rhinitis (runny nose), conjunctivitis (reddening and inflammation of the white of the eye), bronchospasm (excessive and prolonged contraction of the airway muscles) and anaphylaxis (severe allergic reaction) may also occur. When handling the powder preparation, inhalation of the powder should be avoided as this may lead to allergic sensitization and the potential development of allergies. The HMPC recommended that ispaghula husk should not be used in patients with a sudden change in bowel habit that persists for more than two weeks, and in patients with undiagnosed bleeding of the rectum and failure to pass stools following the use of a laxative. It should also not be used in patients with conditions that involve a narrowing of the stomach and gut, and patients who have difficulty swallowing or have problems with their throat. Further information on the risks associated with ispaghula husk medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab 'All documents'. How are ispaghula husk medicines approved in the EU? Any applications for the licensing of medicines containing ispaghula husk have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. Information on the use and licensing of ispaghula husk medicines in EU Member States should be obtained from the relevant national authorities. Other information about ispaghula husk medicines Further information on the HMPC assessment of ispaghula husk medicines, including details of the Committee's conclusions, can be found under the tab 'All documents'. For more information about treatment with ispaghula husk medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. Ispaghula husk - Summary for the public Reference Number: EMA/HMPC/313600/2013 English (EN) (87.46 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Other languages (22) български (BG) (126.74 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View español (ES) (143.72 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View čeština (CS) (115.19 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View dansk (DA) (95.86 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Deutsch (DE) (97.65 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View eesti (ET) (96.36 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View ελληνικά (EL) (122.41 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View français (FR) (99.5 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View hrvatski (HR) (116.68 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View italiano (IT) (95.75 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View latviešu (LV) (142.99 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View lietuvių (LT) (119.71 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View magyar (HU) (118.05 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Malti (MT) (121.91 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Nederlands (NL) (94.97 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View polski (PL) (122.49 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View português (PT) (95.79 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View română (RO) (118.14 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View slovenčina (SK) (121.63 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View slovenščina (SL) (117.15 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View suomi (FI) (94.34 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View svenska (SV) (95.03 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View
EMA-SEED · European Medicines Agency · HMPC
Complete official Overview on psyllium seed, including all clinical, identity, risk and approval paragraphs plus displayed summary metadata; not the full assessment report or linked trials
URL: https://www.ema.europa.eu/en/medicines/herbal/psyllii-semen Publisher: European Medicines Agency · HMPC Source date: 2013; public summary published2014-06-16 Captured: 2026-10-18T17:00:44.624169+00:00 Scope: Complete official Overview on psyllium seed, including all clinical, identity, risk and approval paragraphs plus displayed summary metadata; not the full assessment report or linked trials Actual HTTP status: 200 Overview This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of psyllium seed. The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing psyllium seed. This summary is not intended to provide practical advice on how to use medicines containing psyllium seed. For practical information about using psyllium seed medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist. Expand section Collapse section What is psyllium seed? Psyllium seed is the common name for the seed of the plant Plantago afra L. or Plantago indica L. The plant is cultivated or gathered to obtain the seeds for medicinal use. Psyllium seed is used in the form of ripe, whole, dry seeds or as preparations made by powdering the seeds. Herbal medicines containing psyllium seed are usually available in solid forms to be taken by mouth. What are the HMPC conclusions on its medicinal uses? The HMPC concluded that psyllium seed can be used for the treatment of habitual constipation (constipation not caused by a physical change to an organ) and in conditions where softening of the stools is desirable to reduce pain when they are passed, such as anal fissures, haemorrhoids and after surgery to the anus or rectum. Psyllium seed should be taken with plenty of liquid. It should be taken during the day at least half an hour to one hour before or after taking other medicines and not immediately before bed-time. It can be used in adults or children over the age of 6 years. If constipation does not resolve after 3 days, advice from a doctor or pharmacist should be sought. Detailed instruction on how to take psyllium seed medicines and who can use them can be found in the package leaflet that comes with the medicine. How does psyllium seed work as a medicine? Psyllium seeds contain dietary fibre which when mixed with water forms a gel-like mass that works as a mild laxative (medicine used to treat constipation). It moves down the digestive system and makes the stools softer by increasing their water content. At the same time psyllium seed lubricates the intestine, which improves the transit of stools. By increasing the stool bulk it also increases the tension in the bowel wall which will trigger bowel movements. What evidence supports the use of psyllium seed medicines? The HMPC conclusions on the use of psyllium seed medicines for treating habitual constipation and to soften stools are based on their 'well-established use'. This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. In its assessment, the HMPC considered a number of clinical studies with isphagula seed and ispaghula husk which contains similar ingredients to psyllium seed, showing its effect as a mild laxative. The effectiveness of psyllium seed in softening stools is based on its laxative effects and no specific data are available. For detailed information on the studies assessed by the HMPC, see the HMPC assessment report. What are the risks associated with psyllium seed medicines? Side effects have been reported with psyllium seed medicines, including flatulence and abdominal distension (swelling of the belly). There is a risk of a build-up of hard, dry stool, particularly if psyllium seed is swallowed without enough liquid. Allergic reactions including rhinitis (runny nose), conjunctivitis (reddening and inflammation of the white of the eye), bronchospasm (excessive and prolonged contraction of the airway muscles) and anaphylaxis (severe allergic reaction) may also occur. When handling the powder preparation, inhalation of the powder should be avoided as this may lead to allergic sensitization and the potential development of allergies. The HMPC recommended that psyllium seed medicines should not be used in patients with a sudden change in bowel habit that continues for more than 2 weeks, and in patients with unexplained bleeding from the rectum and failure to pass stools after using a laxative. It should also not be used in patients with conditions that involve a narrowing of the stomach and gut, and patients who have difficulty swallowing or have problems with their throat. Further information on the risks associated with psyllium seed medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab 'All documents'. How are psyllium seed medicines approved in the EU? Any applications for the licensing of medicines containing psyllium seeds have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. Information on the use and licensing of psyllium seed medicines in EU Member States should be obtained from the relevant national authorities. Other information about psyllium seed medicines Further information on the HMPC assessment of psyllium seed medicines, including details of the Committee's conclusions, can be found under the tab 'All documents'. For more information about treatment with psyllium seed medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist. Psyllium seed - Summary for the public Reference Number: EMA/HMPC/322933/2013 English (EN) (85.24 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Other languages (22) български (BG) (112.05 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View español (ES) (84.46 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View čeština (CS) (107.63 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View dansk (DA) (83.4 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Deutsch (DE) (84.39 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View eesti (ET) (82.62 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View ελληνικά (EL) (107.97 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View français (FR) (84.29 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View hrvatski (HR) (101.25 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View italiano (IT) (106.08 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View latviešu (LV) (106.9 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View lietuvių (LT) (106.25 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View magyar (HU) (100.58 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Malti (MT) (106.66 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View Nederlands (NL) (76.75 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View polski (PL) (108.32 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View português (PT) (82.52 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View română (RO) (103.53 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View slovenčina (SK) (104.3 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View slovenščina (SL) (99.6 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View suomi (FI) (82.58 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View svenska (SV) (104.72 KB - PDF) First published: 16/06/2014 Last updated: 16/06/2014 View
P017 · Produktdeklaration
Läs produktdeklarationen på ActiQs
Inulin, kiwifruktpulver (Actinidia deliciosa), psylliumhuskpulver (Plantago psyllium), akaciagummi, grön bananmjöl (Musa × paradisiaca), kalcium (kalciumkarbonat).
Innehåll Per påse (6 g) %DRI* Inulin 2 250 mg ** Kiwifruktpulver 1 200 mg ** Psylliumhuskpulver 1 000 mg ** Akaciagummi 500 mg ** Grön bananmjöl 500 mg ** Kalcium 120 mg 15 %
P057 · Produktdeklaration
Läs produktdeklarationen på ActiQs
Supplement Facts Serving Size: 4 Capsules Serving Per Container: 25 Amount Per Serving %Daily Value Proprietary Blend Bentonite NF, Psyllium (Plantago ovata) (husk), Wheat Grass (Tritucum aestivum) (leaves), Alfalfa (Medicago sativa) (leaves), Cascara Sagrada (Rhamnus purshiana) (bark), Buckthorn (Rhamnus frangula) (bark), Rhubarb (Rheum palmatum) (root), Fennel (Foeniculum vulgare) (seed), Aloe Vera (Aloe barbadensis) (leaf), Leprino Whey, Citrus pectin cellulose, Oat bran powder. 2,000 mg ** **Daily Value not established.
Gelatin (bovine), vegetable magnesium stearate, silicon dioxide, maltodextrin. Contains naturally harvested herbal products. Allergen certification - This product contains dairy derivatives (whey). Guaranteed no added: Sugar, yeast, soy, gluten, fish, tree nuts, peanuts, egg, fragrance, artificial colors or flavors, preservatives, crustacean shellfish. Sodium free.
P077 · Produktdeklaration
Läs produktdeklarationen på ActiQs
Supplement Facts Serving Size: 1 tbsp (8.7 g) Serving Per Container: 20 Amount Per Serving %DV Proprietary Blend † Organic Flax Seed 3,075 mg † Organic Psyllium Husk 1,501 mg † Organic Chia Seed 1,244 mg † Organic Apple Fiber 837 mg † Organic Fennel Seed 486 mg † Organic Black Walnut Hull 432 mg † Organic Cactus Nopal 260 mg † Organic Marshmallow Root 216 mg † Organic Milk Thistle 171 mg † Organic Wormwood Herb 87 mg † Organic Turmeric 54 mg † †Daily Value (DV) not established.
Organic gum acacia, organic natural pineapple flavor, organic monk fruit extract. Contains tree nuts (walnut). Pure planet products are pure, Non GMO and 100% natural. We use no binders, fillers, excipients or flow agents. Our products never contain pesticides, herbicides or chemicals of any kind.
P097 · Produktdeklaration
Läs produktdeklarationen på ActiQs
Supplement Facts Serving Size: 1 Scoop (34 g) Servings Per Container: 30 Amount Per Serving %Daily Value Calories 130 Total Fat 3 g 4%** Saturated Fat 1 g 5%** Total Carbohydrates 4 g 1%** Dietary Fiber 1 g 4%** Total Sugars 0 g ** Includes 0 g Added Sugars 0%** Protein 23 g Calcium 71 mg 5% Iron 6 mg 34% Sodium 660 mg 29% Potassium 587 mg 12% **Percent Daily Values are based on a 2,000 calorie diet.
Raw pea protein isolate (sprouted), sunflower oil creamer (sunflower oil (with natural tocopherols), maltodextrin, modified food starch, mono & diglycerides, tri-calcium phosphate), natural flavors, sodium chloride, mct oil powder, cinnamon powder, stevia extract, vegetable gums (guar gum, cellulose gum, carrageenan), psyllium seed powder. Manufactured in GMP certified facility from domestic & foreign ingredients. Allergen Information: This products is manufactured on the same equipment that processes peanuts, tree nuts, and other common allergens.